Cargando…

FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change

Variability in 3-month changes in FVC was examined in 954 patients with IPF (n=3966 observations) from phase 3 trials; concurrent 3-month decline in the FVC and 6MWD (n=1321 observations) predicted further decline in FVC over the subsequent 3 months http://bit.ly/2GfBKW3

Detalles Bibliográficos
Autores principales:	Nathan, Steven D., Yang, Ming, Morgenthien, Elizabeth A., Stauffer, John L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2020
Materias:	Agora
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236864/ https://www.ncbi.nlm.nih.gov/pubmed/32029447 http://dx.doi.org/10.1183/13993003.02151-2019

Ejemplares similares

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2019)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

The use of online visual analogue scales in idiopathic pulmonary fibrosis
por: Moor, Catharina C., et al.
Publicado: (2022)

Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis
por: Stewart, Iain D., et al.
Publicado: (2021)

Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis
por: Jacob, Joseph, et al.
Publicado: (2019)

Single-cell RNA sequencing identifies G-protein coupled receptor 87 as a basal cell marker expressed in distal honeycomb cysts in idiopathic pulmonary fibrosis
por: Heinzelmann, Katharina, et al.
Publicado: (2022)

Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing
por: Kato, Kosuke, et al.
Publicado: (2021)

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour
por: Sun, Thomas Yang, et al.
Publicado: (2022)

Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration?
por: Eapen, Mathew Suji, et al.
Publicado: (2020)

Changes in Neutrophil–Lymphocyte or Platelet–Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis
por: Nathan, Steven D., et al.
Publicado: (2021)

Eradication success for non-tuberculous mycobacteria in children with cystic fibrosis
por: Hughes, Dominic A., et al.
Publicado: (2021)

Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19
por: Combet, Margot, et al.
Publicado: (2020)

Opioids for breathlessness: psychological and neural factors influencing response variability
por: Abdallah, Sara J., et al.
Publicado: (2019)

Cardiopulmonary exercise testing might be helpful for interpretation of impaired pulmonary function in recovered COVID-19 patients
por: Gao, Yi, et al.
Publicado: (2021)

Bile acid aspiration in people with cystic fibrosis before and after lung transplantation
por: Brodlie, Malcolm, et al.
Publicado: (2015)

Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population
por: Taylor-Robinson, David C., et al.
Publicado: (2014)

An observational study of the lung clearance index throughout childhood in cystic fibrosis: early years matter
por: Davies, Gwyneth, et al.
Publicado: (2020)

Prevalence of pulmonary embolism on hospital admission in COVID-19 patients: is there a role for pre-test probability scores and home treatment?
por: Porfidia, Angelo, et al.
Publicado: (2021)

Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission and role for pre-test probability scores and home treatment
por: Jevnikar, Mitja, et al.
Publicado: (2021)

Pulmonary embolism in patients with COVID-19 pneumonia
por: Bompard, Florian, et al.
Publicado: (2020)

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations
por: Hardisty, Gareth R., et al.
Publicado: (2021)

Interleukin-6 and intrapulmonary shunt
por: Perez-Vizcaino, Francisco, et al.
Publicado: (2021)

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Oral iron supplementation with ferric maltol in patients with pulmonary hypertension
por: Olsson, Karen M., et al.
Publicado: (2020)

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge
por: Mo, Xiaoneng, et al.
Publicado: (2020)

Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission
por: Jevnikar, Mitja, et al.
Publicado: (2021)

Impaired pulmonary function in discharged patients with COVID-19: more work ahead
por: Chen, Ruchong, et al.
Publicado: (2020)

Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?
por: Sofianopoulou, Eleni, et al.
Publicado: (2020)

In vivo demonstration of pulmonary microvascular involvement in COVID-19 using dual-energy computed tomography
por: Si-Mohamed, Salim, et al.
Publicado: (2020)

Pulmonary embolism in COVID-19: D-dimer threshold selection should not be based on maximising Youden's index
por: Korevaar, Daniël A., et al.
Publicado: (2021)

Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia
por: Larsson, Susanna C., et al.
Publicado: (2021)

Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis
por: LaCamera, Peter P, et al.
Publicado: (2019)

Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV
por: Kerkhoff, Andrew D., et al.
Publicado: (2020)

Shunt-type plexiform lesions identified in the Sugen5416/hypoxia rat model of pulmonary arterial hypertension using synchrotron-based phase-contrast micro-CT
por: van der Have, Oscar, et al.
Publicado: (2022)

Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis
por: Lassenius, Mariann I., et al.
Publicado: (2019)

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review
por: Assefa, Yibeltal, et al.
Publicado: (2018)

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Intrapulmonary bronchopulmonary anastomoses in COVID-19 respiratory failure
por: Galambos, Csaba, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mteq1889tj5k7fts64213q8c5a